Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY January 2024 slide deck - over 120 panc pts studied

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Apr 02, 2024 1:10pm

75 Views

Post# 35965527

RE:RE:RE:RE:ONCY January 2024 slide deck - over 120 panc pts studied

As a general reminder of pelareorep's evolving safety and effectiveness -

ONCY's Phase 2 Goblet study PDAC cohort involving pelareorep with atezolizumab resulted in the following data:

- Objective Response Rate (ORR) of 62% (54% confirmed by two or more scans)
- A Disease Control Rate (DCR) of 85%

Survival data: Evaluated based on 4 parameters including:

- Median duration of response was 5.7 months
- Median progression-free survival (PFS) was 7.2 months
- Interim 12-month survival rate was 46%
- Interim median overall survival (OS) was 10.6 months

This move by the FDA demonstrates that the Agency views pancreatic cancer as a significant (rare) disease with an unmet treatment need which appears responsive to checkpoint inhibitor therapy in combination with an immune stimulator.